Searching for a cure, Improving lives

Positive Preclinical Research on the Edasalonexent (CAT-1004) Program

Posted on: January 6th, 2017 | 0 comments

 

Catabasis announced the publication of preclinical data on the edasalonexent program, a potential disease-modifying therapy for Duchenne muscular dystrophy. Edasalonexent (CAT-1004) is an oral small molecule that has the potential to be a disease-modifying therapy for all patients affected by Duchenne muscular dystrophy (DMD or Duchenne), regardless of their underlying mutation.

The preclinical data demonstrates that edasalonexent is effective in ameliorating the dystrophic process in two animal models (dog and mouse) with Duchenne. This research was led by H. Lee Sweeney, Ph.D., then at the University of Pennsylvania. He said the following about the drug:

“There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression. The orally bioavailable NF-kB inhibitors, edasalonexent and CAT-1041, improve the severe dystrophic phenotype found in both mechanically-damaged mdx mice and a GRMD dog and create an environment that can support more successful muscle regeneration. We believe that these in vivo preclinical results support edasalonexent as a candidate for the treatment of DMD.”

The full story can be found here. Action Duchenne will be following this closely and will keep the community updated on developments.

Leave a Reply

Your email address will not be published. Required fields are marked *

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

First draft of agenda announced – Action Duchenne International Conference

June 28th, 2017

We are extremely excited to announce the first draft of the agenda for the Action

Tell me more

Sarepta announces its partner, Genethon, published new micro-dystrophin gene therapy data

July 28th, 2017

Data show for the first time a systemic therapeutic effect in DMD dogs using a

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne